Curis prices $5.6 million offering of stock, pre-funded and common warrants

Curis, Inc. priced a public offering on August 12, 2026 under a prospectus filed pursuant to Rule 424(b)(4). The offering covers 335,001 shares of common stock and, for certain purchasers, 3,398,333 pre-funded warrants together with 3,733,334 common warrants, at a combined public offering price of $1.50 per share and warrant, or $1.49 per pre-funded warrant and warrant.¹

Each August 2026 Warrant carries an exercise price of $1.75 per share, is immediately exercisable, and expires five years from issuance.¹ Total public offering proceeds are listed at $5,600,000, with placement agent fees of $364,000 and proceeds to the company, before expenses, of $5,236,000.¹ Curis estimates net proceeds of approximately $4.8 million after fees and expenses.¹

The company engaged A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd. as exclusive placement agents.¹ Curis expects to deliver the securities to purchasers on or about August 14, 2026, subject to satisfaction of certain conditions.¹

The company said it intends to use the net proceeds to fund research and development activities and for working capital and general corporate purposes.¹ Curis is developing emavusertib (CA-4948), and had an accumulated deficit of $1.3 billion as of March 31, 2026, with a net loss of $24.2 million for the quarter and $9.0 million of cash used in operations.¹ As of March 31, 2026, the company had $15.0 million in cash and cash equivalents, which it said, without the anticipated offering proceeds, would fund existing operations into the fourth quarter of 2026.¹ Curis said these factors raise substantial doubt regarding its ability to continue as a going concern, and that the offering's proceeds will not be sufficient to alleviate that doubt beyond the next 12 months.¹